Read Summary

The tyrosine-kinase inhibitor imatinib used to treat chronic myeloid leukemia and other cancers may help preserve beta-cell function in people with recently diagnosed type 1 diabetes, according to findings from a phase 2 study.
Reuters Health Information

Print Friendly, PDF & Email